Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

BeOne Medicines (6160 HK): Strong1Q26 Result Leads to Guidance Raise in Catalyst Heavy FY

BeiGene (6160 HK): Brukinsa Extend Lead in US, Robust Pipeline, Positive Guidance Revision

BeOne (6160 HK): Shares Are Breaking Into New Highs. Should You Buy?

BeiGene (6160 HK): Brukinsa Outpaces Competitor in 4Q US Sales; Solid Guidance for 2025

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/beigene-ltd" target="_blank" data-smartkarma-citation="entities:27352:1" rel="noopener">BeiGene (6160 HK)</a> reported 2025 revenues of $5.3B, up 40% YoY driven primarily by growth in Brukinsa (zanubrutinib) sales in the U.S. and Europe.</li>
<li>In 2025, sale of Brukinsa was $3.9B, up 49% YoY. For five consequtive quarters now, Brukinsa outpaced its closest competitor Calquence which reported global revenue of $3.5B in 2025.</li>
<li>The company’s second CLL drug candidate, Sonrotoclax has received first global approval in China for relapsed/refractory (R/R) MCL, CLL &amp; SLL.</li>
</ul>



BeiGene (6160 HK) reported 2025 revenues of $5.3B, up 40% YoY driven primarily by growth in Brukinsa (zanubrutinib) sales in the U.S. and Europe.
In 2025, sale of Brukinsa was $3.9B, up 49% YoY. For five consequtive quarters now, Brukinsa outpaced its closest competitor Calquence which reported global revenue of $3.5B in 2025.
The company’s second CLL drug candidate, Sonrotoclax has received first global approval in China for relapsed/refractory (R/R) MCL, CLL &amp; SLL.


BeiGene (6160 HK): Brukinsa Growth Momentum Lifts 2025, 2026 Guidance Announced